z-logo
open-access-imgOpen Access
Effects of SERCA and PMCA inhibitors on the survival of rat cochlear hair cells during ischemia in vitro
Author(s) -
Nyamaa Amarjargal,
Birgit Mazurek,
H. Haupt,
Н. И. Андреева,
Julia Fuchs,
Johann Gross
Publication year - 2008
Publication title -
physiological research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.647
H-Index - 70
eISSN - 1802-9973
pISSN - 0862-8408
DOI - 10.33549/physiolres.931259
Subject(s) - thapsigargin , cyclopiazonic acid , serca , endocochlear potential , vanadate , cochlea , chemistry , calcium , plasma membrane ca2+ atpase , ischemia , calcium in biology , hair cell , endoplasmic reticulum , medicine , endocrinology , atpase , microbiology and biotechnology , biology , biochemistry , anatomy , enzyme
An important mechanism underlying cochlear hair cell (HC)susceptibility to hypoxia/ischemia is the influx of Ca2+. Two mainATP-dependent mechanisms contribute to maintaining low Ca2+levels: uptake of Ca2+ into intracellular stores via smoothendoplasmic reticulum calcium ATPase (SERCA) and extrusion ofCa2+ via plasma membrane calcium ATPase (PMCA). The effectsof the SERCA inhibitors thapsigargin (10 nM-10 µM) andcyclopiazonic acid (CPA; 10-50 µM) and of the PMCA blockerseosin (1.5-10 µM) and o-vanadate (1-5 mM) on inner and outerhair cells (IHCs/OHCs) were examined in normoxia and ischemiausing an in vitro model of the newborn rat cochlea. Exposure ofthe cultures to ischemia resulted in a significant loss of HCs.Thapsigargin and CPA had no effect. Eosin decreased thenumbers of IHCs and OHCs by up to 25 % in normoxia andsignificantly aggravated the ischemia-induced damage to IHCs at5 and 10 µM and to OHCs at 10 µM. o-Vanadate had no effect onIHC and OHC counts in normoxia, but aggravated the ischemiainduced HC loss in a dose-dependent manner. The effects ofeosin and o-vanadate indicate that PMCA has an important roleto play in protecting the HCs from ischemic cell death.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here